Positive phase III results for Lilly’s tirzepatide in type 2 diabetes

Positive phase III results for Lilly’s tirzepatide in type 2 diabetes

Lilly has announced positive first data from two phase III trials, showing that tirzepatide led to significant reductions in HbA1c and body weight reductions from baseline in people with type 2 diabetes.

The positive results from the trials demonstrate tirzepatide’s potential to lower HbA1C and body weight in people with type 2 diabetes who are at the point in their treatment journey where they would progress to an injectable therapy.

In the 52-week SURPASS-3 study, the highest dose of tirzepatide (15mg) reduced HbA1C by 2.37% and body weight by 12.9kg (28.4lb., 13.9%) vs HbA1C reduction of 1.34% and weight gain of 2.3kg with insulin degludec. More data and information on the safety profile are included in the attached release.

Tirzepatide is a novel investigational glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist that integrates the actions of both incretins into a single molecule, representing a new class of medicines being studied for the treatment of type 2 diabetes. GIP is a hormone that may complement the effects of GLP-1 receptor agonists. In preclinical models, GIP has been shown to decrease food intake and increase energy expenditure therefore resulting in weight reductions, and when combined with a GLP-1 receptor agonist, may result in greater effects on glucose and body weight.

Mike Mason, president, Lilly Diabetes said: “Tirzepatide delivered impressive HbA1C and body weight reductions in both studies and continued to achieve consistent efficacy and safety results in people living with type 2 diabetes, regardless of 2 how long they have had the condition. Significantly lowering HbA1C levels and weight are high priorities throughout the type 2 diabetes treatment journey, and the results we have seen from three SURPASS studies to date fuel our belief in tirzepatide’s ability to meet those needs.”